These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 17391248

  • 1. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools.
    Sudo H, Ozaki K, Muramatsu H, Kamei K, Yogo K, Cynshi O, Koga H, Itoh Z, Omura S, Takanashi H.
    Neurogastroenterol Motil; 2007 Apr; 19(4):318-26. PubMed ID: 17391248
    [Abstract] [Full Text] [Related]

  • 2. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs.
    Ozaki K, Sudo H, Muramatsu H, Yogo K, Kamei K, Koga H, Itoh Z, Omura S, Takanashi H.
    Inflammopharmacology; 2007 Feb; 15(1):36-42. PubMed ID: 17323194
    [Abstract] [Full Text] [Related]

  • 3. Effects of mitemcinal (GM-611), an acid-resistant nonpeptide motilin receptor agonist, on the gastrointestinal contractile activity in conscious dogs.
    Ozaki K, Yogo K, Sudo H, Onoma M, Kamei K, Akima M, Koga H, Itoh Z, Omura S, Takanashi H.
    Pharmacology; 2007 Feb; 79(4):223-35. PubMed ID: 17426410
    [Abstract] [Full Text] [Related]

  • 4. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
    Onoma M, Yogo K, Ozaki K, Kamei K, Akima M, Koga H, Itoh Z, Omura S, Takanashi H.
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):35-42. PubMed ID: 18047625
    [Abstract] [Full Text] [Related]

  • 5. Stimulatory action of mitemcinal (GM-611), an acid-resistant non-peptide motilin receptor agonist, on colonic motor activity and defecation: spontaneous and mitemcinal-induced giant migrating contractions during defecation in dogs.
    Hirabayashi T, Morikawa Y, Matsufuji H, Hoshino K, Hagane K, Ozaki K.
    Neurogastroenterol Motil; 2009 Oct; 21(10):1085-e91. PubMed ID: 19508333
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro pharmacological characterization of mitemcinal (GM-611), the first acid-resistant non-peptide motilin receptor agonist, in smooth muscle of rabbit small intestine.
    Takanashi H, Yogo K, Ozaki K, Koga H, Itoh Z, Omura S.
    Pharmacology; 2007 Oct; 79(3):137-48. PubMed ID: 17183187
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.
    Ozaki K, Monnai M, Onoma M, Muramatsu H, Yogo K, Watanabe T, Oda Y, Katagiri K, Arakawa H, Itoh Z, Omura S, Takanashi H.
    J Diabetes Complications; 2008 Oct; 22(5):339-47. PubMed ID: 18413164
    [Abstract] [Full Text] [Related]

  • 10. Nonlinear intestinal pharmacokinetics of mitemcinal, the first acid-resistant non-peptide motilin receptor agonist, in rats.
    Saitoh R, Miyayama T, Mitsui T, Akiba Y, Higashida A, Takata S, Kawanishi T, Aso Y, Itoh Z, Omura S.
    Xenobiotica; 2007 Dec; 37(12):1421-32. PubMed ID: 17926229
    [Abstract] [Full Text] [Related]

  • 11. An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.
    Ozaki K, Onoma M, Muramatsu H, Sudo H, Yoshida S, Shiokawa R, Yogo K, Kamei K, Cynshi O, Kuromaru O, Peeters TL, Takanashi H.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):185-92. PubMed ID: 19445919
    [Abstract] [Full Text] [Related]

  • 12. Effects of motilin and mitemcinal (GM-611) on gastrointestinal contractile activity in rhesus monkeys in vivo and in vitro.
    Yogo K, Ozaki K, Takanashi H, Koto M, Itoh Z, Omura S.
    Dig Dis Sci; 2007 Nov 01; 52(11):3112-22. PubMed ID: 17431782
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis.
    Takanashi H, Cynshi O.
    Regul Pept; 2009 Jun 05; 155(1-3):18-23. PubMed ID: 19345243
    [Abstract] [Full Text] [Related]

  • 17. Characterization of multinuclear hepatocytes induced in rats by mitemcinal (GM-611), an erythromycin derivative.
    Hayashi S, Fujii E, Kato A, Kimura K, Mizoguchi K, Suzuki M, Sugimoto T, Takanashi H, Itoh Z, Omura S, Wanibuchi H.
    Toxicol Pathol; 2008 Oct 05; 36(6):858-65. PubMed ID: 18776165
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study.
    Fujii E, Kimura K, Mizoguchi K, Kato A, Takanashi H, Itoh Z, Omura S, Suzuki M.
    Toxicol Appl Pharmacol; 2008 Apr 01; 228(1):1-7. PubMed ID: 18355581
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
    Sanger GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S, Näslund E, Hellström PM, Borman RA, Unsworth WP, Matthews KL, Lee K.
    Neurogastroenterol Motil; 2009 Jun 01; 21(6):657-64, e30-1. PubMed ID: 19374732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.